BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

...cell inducer and a T cell activator.Cambridge accelerator Start Codon closes first fundU.K.-based life sciences accelerator Start Codon...
...million ($19.8 million). Novartis AG (NYSE:NVS; SIX:NOVN) and Cambridge Innovation Capital were among its LPs. Start Codon...
...shares in the deal. TARGETSC3 - Complement 3NMT – N-myristoyltransferase BC Staff Lead Pharma Holding B.V. Apellis Pharmaceuticals Inc. BeyondSpring Inc. Start Codon Myricx...
BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...Cambridge to develop next generation antibody-drug conjugate (ADC) therapeutics to treat multiple cancers. Meltwind and Start Codon...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...of the Milner Therapeutics Institute, a Cambridge-based translational research hub. On April 23, Milner launched Start Codon...
BioCentury | Apr 23, 2019
Finance

Accelerating innovations in Cambridge

...to provide capital, mentorship and lab space to young companies. That’s the rationale for launching Start Codon...
...investor group that includes CIC, Genentech Inc. and research campus operator Babraham Bioscience Technologies Ltd., Start Codon...
...regular basis, so we see Start Codon as an extension of CIC for early stage opportunities.” Start Codon’s...
BioCentury | May 14, 2001
Company News

Athersys other research news

...promoters and express proteins from endogenous genes - even those that do not contain a start codon...
Items per page:
1 - 5 of 5
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

...cell inducer and a T cell activator.Cambridge accelerator Start Codon closes first fundU.K.-based life sciences accelerator Start Codon...
...million ($19.8 million). Novartis AG (NYSE:NVS; SIX:NOVN) and Cambridge Innovation Capital were among its LPs. Start Codon...
...shares in the deal. TARGETSC3 - Complement 3NMT – N-myristoyltransferase BC Staff Lead Pharma Holding B.V. Apellis Pharmaceuticals Inc. BeyondSpring Inc. Start Codon Myricx...
BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...Cambridge to develop next generation antibody-drug conjugate (ADC) therapeutics to treat multiple cancers. Meltwind and Start Codon...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...of the Milner Therapeutics Institute, a Cambridge-based translational research hub. On April 23, Milner launched Start Codon...
BioCentury | Apr 23, 2019
Finance

Accelerating innovations in Cambridge

...to provide capital, mentorship and lab space to young companies. That’s the rationale for launching Start Codon...
...investor group that includes CIC, Genentech Inc. and research campus operator Babraham Bioscience Technologies Ltd., Start Codon...
...regular basis, so we see Start Codon as an extension of CIC for early stage opportunities.” Start Codon’s...
BioCentury | May 14, 2001
Company News

Athersys other research news

...promoters and express proteins from endogenous genes - even those that do not contain a start codon...
Items per page:
1 - 5 of 5